[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antioxidant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antioxidant":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100649364","vitamin-d-status-and-asthma-control-pulmonary-function-and-oxidative-stress-in-adults-with-bronchial-asthma-100649364",false,"NCT07733635","Vitamin D Status and Asthma Control, Pulmonary Function, and Oxidative Stress in Adults With Bronchial Asthma","Association Between Serum Vitamin D Status, Asthma Control, Pulmonary Function, and Oxidative Stress Biomarkers in Egyptian Adults With Bronchial Asthma: A Cross-Sectional Study","VD-ASTHMA","Inclusion Criteria\n\n* Age ≥ 18 years.\n* Confirmed diagnosis of bronchial asthma.\n* Clinically stable at the time of assessment.\n* Availability of spirometry results.\n* Availability of laboratory investigations including serum 25(OH)D and oxidative stress biomarkers.\n\nExclusion Criteria\n\n* Other chronic pulmonary diseases.\n* Active respiratory infection.\n* Malignancy.\n* Significant renal or hepatic disease.\n* Pregnancy.\n* Current vitamin D supplementation.\n* Other conditions known to markedly influence oxidative stress status.","ALL","18 Years",{"count":20,"type":21},134,"ESTIMATED","OBSERVATIONAL","Asthma is a chronic inflammatory airway disease associated with variable airflow limitation and persistent respiratory symptoms. Vitamin D has been proposed as a potential biomarker related to immune regulation, asthma control, pulmonary function, and oxidative stress balance.\n\nThis prospective cross-sectional observational study aims to investigate the association between serum 25-hydroxyvitamin D \\[25(OH)D\\] concentrations, asthma control, pulmonary function parameters, and erythrocyte oxidative stress biomarkers among Egyptian adults with bronchial asthma.\n\nA total of 200 adult asthma patients will be recruited from Abbassia Chest Hospital, Cairo, Egypt. Participants will undergo clinical assessment, Asthma Control Test (ACT), post-bronchodilator spirometry, serum vitamin D measurement, and oxidative stress biomarker assessment including malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GPx), and reduced glutathione (GSH).\n\nParticipants will be categorized according to serum 25(OH)D concentrations into vitamin D deficient, insufficient, and sufficient groups.\n\nNo intervention or treatment assignment will be performed.\n\n5\\. Detailed Description",[25,26,27,28,29,30],"Bronchial Asthma","Vitamin D Deficiency","Pulmonary Function Impairment","Oxidative Stress","Asthma","Antioxidant",[26,25,32,33,28,34],"Pulmonary Function","Spirometry","Malondialdehyde","NOT_YET_RECRUITING","2026-07-26",{"date":38,"type":39},"2026-07-29","ACTUAL",{"date":36,"type":21},{"date":42,"type":21},"2027-02-25",{"name":44,"class":45},"Sinai University","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100599814","efficacy-and-safety-of-resveratrol-in-patients-with-rheumatoid-arthritis-100599814","NCT07089381","Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.","Inclusion Criteria:\n\n* Adult patients \\> 18 years old\n* Established diagnosis of RA according to American College of Rheumatology\u002FEuropean league Against Rheumatism (ACR\u002FEULAR) 2010 criteria (Aletaha et al., 2010), presented with moderate to high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) \\>3.2.\n* Patients receiving stable regimen of one or more csDMARDs for at least the past 3 months.\n* RA Patients with Moderate or high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) \\>3.2.\n\nExclusion Criteria:\n\n* Patients receiving biologic DMARDs therapy for RA\n* Patients taking any other anti-inflammatory drugs\n* Patients taking any other antioxidants\n* Pregnant and lactating women\n* Other rheumatological, inflammatory diseases or malignancies\n* Smokers\n* Thyroid illnesses\n* Patients with impaired liver functions (liver transaminases level ≥ three times upper normal limits), impaired kidney functions (estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin)",{"count":53,"type":21},118,"INTERVENTIONAL",[56],"NA","The aim of the current study is to evaluate the effects of resveratrol on the clinical outcome(s) of patients with moderate rheumatoid arthritis.\n\nObjectives :\n\n1. To investigate the effects of Resveratrol on inflammation and oxidative stress by measuring:\n\n   * Serum Sirtuin 1(SIRT1)\n   * Serum Myeloperoxidase (MPO)\n   * Serum C-reactive protein (CRP)\n2. To investigate the effects of Resveratrol on disease activity by measuring the disease activity (DAS28 score).\n3. To investigate the effect of Resveratrol on improving the quality of life using the Health Assessment Questionnaire Disability index (HAQ-DI).\n4. To assess any adverse effects related to Resveratrol.\n\nPatients:\n\nEligible patients (no=118) will be randomly assigned in a 1:1 ratio to one of two groups:\n\n1. Control group: 59 patients will receive the standard treatment for management of RA for 3 months.\n2. Resveratrol group: 59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix Egypt) (given as one 1000 mg tablets once daily) for 3 months.",[59,60,61,30,62,63,64,65,66],"Rheumatic Arthritis","Rheumatoid Arthritis (RA) Prevention","Inflamation","Anti Oxidative Stress","Anti Aging","C Reactive Protein","Methotrexate","Quality of Life Outcomes","RECRUITING","2025-07-21",{"date":70,"type":39},"2025-07-28",{"date":72,"type":21},"2025-08-01",{"date":74,"type":21},"2026-06-01",{"name":76,"class":45},"Ain Shams University",1]